Find out what you know about which diabetes drugs in which classes show CV protective properties and results of the trials that support their use.
Semaglutide Supports Long-Term Weight Loss, Reduces CV Risk Across BMI Subgroups
Analyses of the SELECT trial found mean weight loss of 10.2% sustained for 4 years and comparable CV benefit with weight loss greater or less than 5%, or even weight gain.
Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care
Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.
FDA Reports More than 200 Injuries Related to Recalled Tandem Diabetes Insulin App
There have been 224 reported injuries as of April 15, 2024, the CDC said, but no reports of death related to the app intermittently crashing and rebooting.
Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?
Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.
Children with HTN Have 2-times Higher Risk of Major Adverse Cardiac Events, According to New Research
Findings suggest that optimizing care for children with hypertension may reduce the risk of adult CVD, report researchers.
CV Risk Prevention Profiles Significantly Worse Following Stroke vs MI in 2 Large National Cohorts
Study participants who had a history of stroke were nearly 60% less likely to meet guideline-recommended secondary prevention goals, new research reveals.